Unidade Local De Saude Da Regiao De Leiria E.P.E.

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)2 trials
• Crohn's disease2 trials
• Amyloidosis1 trial
• Aortic stenosis1 trial
• Coronary artery disease1 trial
• Depression1 trial
• Hypertrophic cardiomyopathy1 trial
• IgA nephropathy1 trial
• Insomnia1 trial
• Lupus (SLE)1 trial
• Multiple sclerosis1 trial
• Psoriasis1 trial
• and 3 more

Phase

• Phase 314 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Completed6 trials
• Active, not recruiting4 trials
• Recruiting4 trials
• Not yet recruiting2 trials

Lead sponsor

• Janssen Research & Development, LLC3 trials
• Merck Sharp & Dohme LLC2 trials
• AbbVie1 trial
• Almirall, S.A.1 trial
• Alnylam Pharmaceuticals1 trial
• and 8 more

Running trials

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Recruiting

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

  NCT07001800· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  NCT06559306· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT03568318· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis1 recruiting
• Aortic stenosis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Crohn's disease1 recruiting
• IgA nephropathy1 recruiting
• Lupus (SLE)1 recruiting

Closed trials

• Completed

  Phase IIa Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients with Rheumatoid Arthritis

  2023-510258-17-00· Phase 2· Solfarcos Solucoes Farmaceuticas E Cosmeticas Lda.· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study

  2024-511560-93-00· Phase 3· Boehringer Ingelheim International GmbH· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source